The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism

Abstract

Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 106) into immune competent syngeneic hosts, but not immune deficient mice. At higher cell numbers (5 × 106 PDV cells), progressively growing tumors were established in 14 of 15 vehicle treated mice while treatment of mice with the PPARγ agonist rosiglitazone resulted in increased tumor rejection (5 of 14 tumors), a significant decrease in PDV tumor size, and a significant decrease in tumor cell Ki67 labeling. Rosiglitazone treatment had no effect on tumor rejection, tumor volume or PDV tumor cell proliferation in immune deficient NOD.CB17-PrkdcSCID/J mice. Rosiglitazone treatment also promoted an increase in tumor infiltrating CD3+ T-cells at both early and late time points. In contrast, rosiglitazone treatment had no significant effect on myeloid cells expressing either CD11b or Gr-1 but suppressed a late accumulation of myeloid cells expressing both CD11b and Gr-1, suggesting a potential role for CD11b+Gr-1+ myeloid cells in the late anti-tumor immune response. Overall, our data provides evidence that the PPARγ agonist rosiglitazone promotes immune-mediated anti-neoplastic activity against tumors derived from this immunogenic CSCC cell line.

FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy

“…1 tumours generated after a subcutaneous injection of 1 × 10 4 MC38 cells resulted in an immune response leading to decreased growth and rejection. Because higher numbers of inoculated cells can result in diminished anti-tumour immune responses 45 we injected 2 × 10 5 MC38 cells and did not see rejection or even differences in tumour growth in WT and Fgf2 LMW−/− mice ( Fig. 7a, Supplementary Fig.…”

Evidence for a non-stochastic two-field hypothesis for persistent skin cancer risk

“…For p16 Ink4a , rabbit polyclonal anti-p16 (1:100, M-156, Santa Cruz Biotechnology) was utilized. Immunofluorescence labeling for pan-cytokeratin expression was performed as previously detailed 31 . Chromogenic immunolabeling using DAB as a substrate was done for p53 immunolabeling.…”

Important players in carcinogenesis as potential targets in cancer therapy: an update

“…An in vitro study on two breast cancer cell lines (A2780, SKOV3) revealed severe apoptosis and tumor growth inhibition in mouse xenografts after combined therapy of rosiglitazone and olaparib [176]. Rosiglitazone also decreased proliferation and tumor size in human squamous cell carcinoma (SCC) xenografts [177]. In turn, Lau et al demonstrated the synergistic impact of rosiglitazone on 5-fluorouracil-induced apoptosis of two colorectal cancer cell lines (HCT-116, HT-29).…”